Premium
Heart transplant recipient patient with COVID‐19 treated with tocilizumab
Author(s) -
Mattioli Massimo,
Fustini Elisa,
Gennarini Silvia
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13380
Subject(s) - tocilizumab , medicine , rash , covid-19 , pneumonia , pulmonary function testing , adverse effect , dermatology , disease , infectious disease (medical specialty)
A heart transplant 62‐year‐old patient referred for coronavirus‐19 disease (COVID‐19) pneumonia. At admission, he was febrile, tachypnoeic, and mild hypoxic with dry cough; during hospitalization, a diffuse morbilliform skin rash appeared. He was treated with tocilizumab with symptoms improvement, without a complete pulmonary function recovery. Skin rash, highly suggestive for COVID‐19 cutaneous involvement, persisted for ten days despite tocilizumab administration.